88 related articles for article (PubMed ID: 11748930)
1. Degradation signals in ErbB-2 dictate proteasomal processing and immunogenicity and resist protection by cis glycine-alanine repeat.
Piechocki MP; Pilon SA; Kelly C; Wei WZ
Cell Immunol; 2001 Sep; 212(2):138-49. PubMed ID: 11748930
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody.
Pilon SA; Piechocki MP; Wei WZ
J Immunol; 2001 Sep; 167(6):3201-6. PubMed ID: 11544306
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of proteasomal degradation by the gly-Ala repeat of Epstein-Barr virus is influenced by the length of the repeat and the strength of the degradation signal.
Dantuma NP; Heessen S; Lindsten K; Jellne M; Masucci MG
Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8381-5. PubMed ID: 10890896
[TBL] [Abstract][Full Text] [Related]
4. Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription.
Bonvini P; An WG; Rosolen A; Nguyen P; Trepel J; Garcia de Herreros A; Dunach M; Neckers LM
Cancer Res; 2001 Feb; 61(4):1671-7. PubMed ID: 11245482
[TBL] [Abstract][Full Text] [Related]
5. Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2.
Piechocki MP; Pilon SA; Wei WZ
J Immunol; 2001 Sep; 167(6):3367-74. PubMed ID: 11544327
[TBL] [Abstract][Full Text] [Related]
6. CYP2E1 degradation by in vitro reconstituted systems: role of the molecular chaperone hsp90.
Goasduff T; Cederbaum AI
Arch Biochem Biophys; 2000 Jul; 379(2):321-30. PubMed ID: 10898951
[TBL] [Abstract][Full Text] [Related]
7. Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes.
Wu Y; Kipps TJ
J Immunol; 1997 Dec; 159(12):6037-43. PubMed ID: 9550402
[TBL] [Abstract][Full Text] [Related]
8. Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL. Implications for tumor immunogenicity.
Castilleja A; Ward NE; O'Brian CA; Swearingen B; Swan E; Gillogly MA; Murray JL; Kudelka AP; Gershenson DM; Ioannides CG
Mol Cell Biochem; 2001 Jan; 217(1-2):21-33. PubMed ID: 11269662
[TBL] [Abstract][Full Text] [Related]
9. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin.
Mimnaugh EG; Chavany C; Neckers L
J Biol Chem; 1996 Sep; 271(37):22796-801. PubMed ID: 8798456
[TBL] [Abstract][Full Text] [Related]
10. The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association.
Nagata Y; Anan T; Yoshida T; Mizukami T; Taya Y; Fujiwara T; Kato H; Saya H; Nakao M
Oncogene; 1999 Oct; 18(44):6037-49. PubMed ID: 10557093
[TBL] [Abstract][Full Text] [Related]
11. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA.
Wei WZ; Shi WP; Galy A; Lichlyter D; Hernandez S; Groner B; Heilbrun L; Jones RF
Int J Cancer; 1999 May; 81(5):748-54. PubMed ID: 10328228
[TBL] [Abstract][Full Text] [Related]
12. Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo.
Whitesell L; Sutphin P; An WG; Schulte T; Blagosklonny MV; Neckers L
Oncogene; 1997 Jun; 14(23):2809-16. PubMed ID: 9190897
[TBL] [Abstract][Full Text] [Related]
13. Geldanamycin-induced destabilization of Raf-1 involves the proteasome.
Schulte TW; An WG; Neckers LM
Biochem Biophys Res Commun; 1997 Oct; 239(3):655-9. PubMed ID: 9367823
[TBL] [Abstract][Full Text] [Related]
14. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS
Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988
[TBL] [Abstract][Full Text] [Related]
15. Regulated Co-translational ubiquitination of apolipoprotein B100. A new paradigm for proteasomal degradation of a secretory protein.
Zhou M; Fisher EA; Ginsberg HN
J Biol Chem; 1998 Sep; 273(38):24649-53. PubMed ID: 9733761
[TBL] [Abstract][Full Text] [Related]
16. Identification of ErbB-2 kinase domain motifs required for geldanamycin-induced degradation.
Tikhomirov O; Carpenter G
Cancer Res; 2003 Jan; 63(1):39-43. PubMed ID: 12517775
[TBL] [Abstract][Full Text] [Related]
17. Heregulin beta1 induces the down regulation and the ubiquitin-proteasome degradation pathway of p185HER2 oncoprotein.
Magnifico A; Tagliabue E; Ardini E; Casalini P; Colnaghi MI; Ménard S
FEBS Lett; 1998 Jan; 422(2):129-31. PubMed ID: 9489990
[TBL] [Abstract][Full Text] [Related]
18. A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins.
Quaglino E; Mastini C; Amici A; Marchini C; Iezzi M; Lanzardo S; De Giovanni C; Montani M; Lollini PL; Masucci G; Forni G; Cavallo F
Cancer Res; 2010 Apr; 70(7):2604-12. PubMed ID: 20332241
[TBL] [Abstract][Full Text] [Related]
19. Antitumor response elicited by a superantigen-transmembrane sequence fusion protein anchored onto tumor cells.
Wahlsten JL; Mills CD; Ramakrishnan S
J Immunol; 1998 Dec; 161(12):6761-7. PubMed ID: 9862706
[TBL] [Abstract][Full Text] [Related]
20. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts.
Nagata Y; Furugen R; Hiasa A; Ikeda H; Ohta N; Furukawa K; Nakamura H; Furukawa K; Kanematsu T; Shiku H
J Immunol; 1997 Aug; 159(3):1336-43. PubMed ID: 9233630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
